TORONTO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...

— Clinical evidence continues to highlight TULSA’s ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH — “The various presentations made at AUA and other major ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Windsong Radiology Group President Dr. Raja Cheruvu became ...

TORONTO, July 11, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...

Arun Menawat, CEO of Profound Medical, talks about the company’s innovative TULSA-PRO technology. In a recent interview, Arun Menawat, CEO of Profound Medical, discussed the company’s innovative TULSA ...

Traditional surgical and radiological approaches – along with a growing number of emerging technologies – to prostate cancer have made it a controllable disease for many men. At the same time, the ...

SSM Health Saint Louis University Hospital recently performed the first transurethral ultrasound ablation (TULSA) procedure in Missouri as well as the larger Midwest region. It’s a minimally invasive ...

Credit: Thinkstock By 5 years, 92% of men recovered pad-free continence, and 87% had preserved erectile function sufficient for penetration. MRI-guided whole-gland transurethral ultrasound ablation ...

— So far this year alone, 25 TULSA-related scientific research presentations have been delivered at major medical meetings around the world — — Of those, eight (8) presentations were from leading ...